Hypomethylation of

Debolina Pal, Subhayan Sur, Rituparna Roy, Suvra Mandal, Chinmay Kumar Panda

Abstract read

In one paragraph

Article in Journal of biosciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it

0cells of the map it votes in

2citing papers in PubMed

0.3field-weighted citation impact, top 44% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

Integration of gene expression and DNA methylation data using MLA-GNN for liver cancer biomarker mining.Frontiers in genetics · 2024
Article
An immune and epigenetics-related scoring model and drug candidate prediction for hepatic carcinogenesis via dynamic network biomarker analysis and connectivity mapping.Computational and structural biotechnology journal · 2023
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Debolina PalDepartment Oncogene Regulation, Chittaranjan National Cancer Institute, Kolkata 700 026, India.

Subhayan Sur

Rituparna Roy

Suvra Mandal

Chinmay Kumar Panda

Chittaranjan National Cancer Institute · INCentral Council for Research in Ayurvedic Science · INSaint Louis University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Amarogentin (active component of

Indexed as

AnimalsAnticarcinogenic AgentsApoptosisCarbon TetrachlorideCarcinogenesisCarcinoma, HepatocellularCell CycleCyclin-Dependent Kinase Inhibitor p16DecitabineDiethylnitrosamineDisease Models, AnimalDNA (Cytosine-5-)-Methyltransferase 1Epigenesis, GeneticFemaleGene Expression Regulation, NeoplasticHep G2 CellsamarogentinAnticarcinogenic AgentsCarbon TetrachlorideCyclin-Dependent Kinase Inhibitor p16DecitabineDiethylnitrosamineDNA (Cytosine-5-)-Methyltransferase 1Dnmt1 protein, mouseHdac1 protein, mouseHdac2 protein, mouseHistone Deacetylase 1Histone Deacetylase 2Intracellular Signaling Peptides and ProteinsIridoidsLimd1 protein, mouseLIM Domain ProteinsPhosphoric Monoester Hydrolases

Identifiers

PMID34148876

OpenAlexW3169078695

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.